ID   CNOT1_HUMAN             Reviewed;        2376 AA.
AC   A5YKK6; Q68DX7; Q7Z3K2; Q8IWB8; Q8TB53; Q9BVZ6; Q9UFR8; Q9UI27; Q9Y2L0;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   15-JAN-2008, sequence version 2.
DT   28-JUN-2023, entry version 143.
DE   RecName: Full=CCR4-NOT transcription complex subunit 1;
DE   AltName: Full=CCR4-associated factor 1;
DE   AltName: Full=Negative regulator of transcription subunit 1 homolog;
DE            Short=NOT1H;
DE            Short=hNOT1;
GN   Name=CNOT1; Synonyms=CDC39, KIAA1007, NOT1; ORFNames=AD-005;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), AND NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 244-2376 (ISOFORM 1).
RC   TISSUE=Cervix, Fetal kidney, and Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 757-2376 (ISOFORM 1), AND VARIANT ALA-603.
RC   TISSUE=Choriocarcinoma, Leiomyosarcoma, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 537-2376 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10231032; DOI=10.1093/dnares/6.1.63;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIII. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 6:63-70(1999).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1964-2374 (ISOFORM 1).
RC   TISSUE=Adrenal gland;
RX   PubMed=10931946; DOI=10.1073/pnas.160270997;
RA   Hu R.-M., Han Z.-G., Song H.-D., Peng Y.-D., Huang Q.-H., Ren S.-X.,
RA   Gu Y.-J., Huang C.-H., Li Y.-B., Jiang C.-L., Fu G., Zhang Q.-H., Gu B.-W.,
RA   Dai M., Mao Y.-F., Gao G.-F., Rong R., Ye M., Zhou J., Xu S.-H., Gu J.,
RA   Shi J.-X., Jin W.-R., Zhang C.-K., Wu T.-M., Huang G.-Y., Chen Z.,
RA   Chen M.-D., Chen J.-L.;
RT   "Gene expression profiling in the human hypothalamus-pituitary-adrenal axis
RT   and full-length cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9543-9548(2000).
RN   [7]
RP   FUNCTION, INTERACTION WITH CNOT2; CNOT4 AND CNOT8, AND TISSUE SPECIFICITY.
RX   PubMed=10637334; DOI=10.1093/nar/28.3.809;
RA   Albert T.K., Lemaire M., van Berkum N.L., Gentz R., Collart M.A.,
RA   Timmers H.T.M.;
RT   "Isolation and characterization of human orthologs of yeast CCR4-NOT
RT   complex subunits.";
RL   Nucleic Acids Res. 28:809-817(2000).
RN   [8]
RP   FUNCTION, DOMAIN, AND INTERACTION WITH CNOT2; CNOT3; CNOT8; ESR1 AND RXRA.
RX   PubMed=16778766; DOI=10.1038/sj.emboj.7601194;
RA   Winkler G.S., Mulder K.W., Bardwell V.J., Kalkhoven E., Timmers H.T.;
RT   "Human Ccr4-Not complex is a ligand-dependent repressor of nuclear
RT   receptor-mediated transcription.";
RL   EMBO J. 25:3089-3099(2006).
RN   [9]
RP   INTERACTION WITH TOB1.
RX   PubMed=18377426; DOI=10.1111/j.1349-7006.2008.00746.x;
RA   Miyasaka T., Morita M., Ito K., Suzuki T., Fukuda H., Takeda S., Inoue J.,
RA   Semba K., Yamamoto T.;
RT   "Interaction of antiproliferative protein Tob with the CCR4-NOT deadenylase
RT   complex.";
RL   Cancer Sci. 99:755-761(2008).
RN   [10]
RP   IDENTIFICATION IN THE CCR4-NOT COMPLEX, AND COMPOSITION OF THE CCR4-NOT
RP   COMPLEX.
RX   PubMed=19558367; DOI=10.1042/bj20090500;
RA   Lau N.C., Kolkman A., van Schaik F.M., Mulder K.W., Pijnappel W.W.,
RA   Heck A.J., Timmers H.T.;
RT   "Human Ccr4-Not complexes contain variable deadenylase subunits.";
RL   Biochem. J. 422:443-453(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   INTERACTION WITH TNRC6A; TNRC6B AND TNRC6C.
RX   PubMed=21981923; DOI=10.1016/j.molcel.2011.09.007;
RA   Braun J.E., Huntzinger E., Fauser M., Izaurralde E.;
RT   "GW182 proteins directly recruit cytoplasmic deadenylase complexes to miRNA
RT   targets.";
RL   Mol. Cell 44:120-133(2011).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH TNRC6C.
RX   PubMed=21984185; DOI=10.1038/nsmb.2149;
RA   Fabian M.R., Cieplak M.K., Frank F., Morita M., Green J., Srikumar T.,
RA   Nagar B., Yamamoto T., Raught B., Duchaine T.F., Sonenberg N.;
RT   "miRNA-mediated deadenylation is orchestrated by GW182 through two
RT   conserved motifs that interact with CCR4-NOT.";
RL   Nat. Struct. Mol. Biol. 18:1211-1217(2011).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH ZFP36.
RX   PubMed=21278420; DOI=10.1093/nar/gkr011;
RA   Sandler H., Kreth J., Timmers H.T., Stoecklin G.;
RT   "Not1 mediates recruitment of the deadenylase Caf1 to mRNAs targeted for
RT   degradation by tristetraprolin.";
RL   Nucleic Acids Res. 39:4373-4386(2011).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21976065; DOI=10.1007/s13238-011-1092-4;
RA   Ito K., Takahashi A., Morita M., Suzuki T., Yamamoto T.;
RT   "The role of the CNOT1 subunit of the CCR4-NOT complex in mRNA
RT   deadenylation and cell viability.";
RL   Protein Cell 2:755-763(2011).
RN   [16]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=22367759; DOI=10.1002/stem.1070;
RA   Zheng X., Dumitru R., Lackford B.L., Freudenberg J.M., Singh A.P.,
RA   Archer T.K., Jothi R., Hu G.;
RT   "Cnot1, Cnot2, and Cnot3 maintain mouse and human ESC identity and inhibit
RT   extraembryonic differentiation.";
RL   Stem Cells 30:910-922(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-318 AND SER-1061, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   INTERACTION WITH EIF4ENIF1.
RX   PubMed=26027925; DOI=10.1016/j.celrep.2015.04.065;
RA   Nishimura T., Padamsi Z., Fakim H., Milette S., Dunham W.H., Gingras A.C.,
RA   Fabian M.R.;
RT   "The eIF4E-Binding protein 4E-T is a component of the mRNA decay machinery
RT   that bridges the 5' and 3' termini of target mRNAs.";
RL   Cell Rep. 11:1425-1436(2015).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH YTHDF2.
RX   PubMed=27558897; DOI=10.1038/ncomms12626;
RA   Du H., Zhao Y., He J., Zhang Y., Xi H., Liu M., Ma J., Wu L.;
RT   "YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the
RT   CCR4-NOT deadenylase complex.";
RL   Nat. Commun. 7:12626-12626(2016).
RN   [20]
RP   INTERACTION WITH EIF4ENIF1.
RX   PubMed=27342281; DOI=10.1093/nar/gkw565;
RA   Kamenska A., Simpson C., Vindry C., Broomhead H., Benard M.,
RA   Ernoult-Lange M., Lee B.P., Harries L.W., Weil D., Standart N.;
RT   "The DDX6-4E-T interaction mediates translational repression and P-body
RT   assembly.";
RL   Nucleic Acids Res. 44:6318-6334(2016).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH EIF4ENIF1.
RX   PubMed=32354837; DOI=10.1101/gad.336073.119;
RA   Raesch F., Weber R., Izaurralde E., Igreja C.;
RT   "4E-T-bound mRNAs are stored in a silenced and deadenylated form.";
RL   Genes Dev. 34:847-860(2020).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 1093-1317 IN COMPLEX WITH CNOT7,
RP   INTERACTION WITH CNOT8; CNOT6 AND CNOT6L, AND MUTAGENESIS OF LYS-1208;
RP   HIS-1212 AND LYS-1218.
RX   PubMed=22977175; DOI=10.1093/nar/gks883;
RA   Petit A.P., Wohlbold L., Bawankar P., Huntzinger E., Schmidt S.,
RA   Izaurralde E., Weichenrieder O.;
RT   "The structural basis for the interaction between the CAF1 nuclease and the
RT   NOT1 scaffold of the human CCR4-NOT deadenylase complex.";
RL   Nucleic Acids Res. 40:11058-11072(2012).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 800-1004 IN COMPLEX WITH ZFP36,
RP   INTERACTION WITH ZFP36, AND FUNCTION.
RX   PubMed=23644599; DOI=10.1038/nsmb.2572;
RA   Fabian M.R., Frank F., Rouya C., Siddiqui N., Lai W.S., Karetnikov A.,
RA   Blackshear P.J., Nagar B., Sonenberg N.;
RT   "Structural basis for the recruitment of the human CCR4-NOT deadenylase
RT   complex by tristetraprolin.";
RL   Nat. Struct. Mol. Biol. 20:735-739(2013).
RN   [24] {ECO:0007744|PDB:5ANR}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1063-1314 IN COMPLEX WITH
RP   EIF4ENIF1 AND DDX6, AND INTERACTION WITH EIF4ENIF1.
RX   PubMed=26489469; DOI=10.1016/j.celrep.2015.09.033;
RA   Ozgur S., Basquin J., Kamenska A., Filipowicz W., Standart N., Conti E.;
RT   "Structure of a human 4E-T/DDX6/CNOT1 complex reveals the different
RT   interplay of DDX6-binding proteins with the CCR4-NOT complex.";
RL   Cell Rep. 13:703-711(2015).
RN   [25]
RP   VARIANT HPE12 CYS-535, AND INVOLVEMENT IN HPE12.
RX   PubMed=31006513; DOI=10.1016/j.ajhg.2019.03.018;
RA   De Franco E., Watson R.A., Weninger W.J., Wong C.C., Flanagan S.E.,
RA   Caswell R., Green A., Tudor C., Lelliott C.J., Geyer S.H., Maurer-Gesek B.,
RA   Reissig L.F., Lango Allen H., Caliebe A., Siebert R., Holterhus P.M.,
RA   Deeb A., Prin F., Hilbrands R., Heimberg H., Ellard S., Hattersley A.T.,
RA   Barroso I.;
RT   "A specific CNOT1 mutation results in a novel syndrome of pancreatic
RT   agenesis and holoprosencephaly through impaired pancreatic and neurological
RT   development.";
RL   Am. J. Hum. Genet. 104:985-989(2019).
RN   [26]
RP   VARIANT HPE12 CYS-535, AND INVOLVEMENT IN HPE12.
RX   PubMed=31006510; DOI=10.1016/j.ajhg.2019.03.017;
RA   Kruszka P., Berger S.I., Weiss K., Everson J.L., Martinez A.F., Hong S.,
RA   Anyane-Yeboa K., Lipinski R.J., Muenke M.;
RT   "A CCR4-NOT transcription complex, subunit 1, CNOT1, variant associated
RT   with holoprosencephaly.";
RL   Am. J. Hum. Genet. 104:990-993(2019).
RN   [27]
RP   VARIANTS VIBOS 26-ARG--SER-2376 DEL; 33-GLN--SER-2376 DEL;
RP   396-TYR--SER-2376 DEL; GLU-642; LYS-897; CYS-900; ILE-1038; LEU-1089;
RP   PRO-1148; GLY-1188; ARG-1241; ALA-1419; SER-1428; CYS-1478; HIS-1494;
RP   ASP-1572 AND SER-2216, AND INVOLVEMENT IN VIBOS.
RX   PubMed=32553196; DOI=10.1016/j.ajhg.2020.05.017;
RG   DDD Study;
RA   Vissers L.E.L.M., Kalvakuri S., de Boer E., Geuer S., Oud M.,
RA   van Outersterp I., Kwint M., Witmond M., Kersten S., Polla D.L.,
RA   Weijers D., Begtrup A., McWalter K., Ruiz A., Gabau E., Morton J.E.V.,
RA   Griffith C., Weiss K., Gamble C., Bartley J., Vernon H.J., Brunet K.,
RA   Ruivenkamp C., Kant S.G., Kruszka P., Larson A., Afenjar A.,
RA   Billette de Villemeur T., Nugent K., Raymond F.L., Venselaar H.,
RA   Demurger F., Soler-Alfonso C., Li D., Bhoj E., Hayes I., Hamilton N.P.,
RA   Ahmad A., Fisher R., van den Born M., Willems M., Sorlin A., Delanne J.,
RA   Moutton S., Christophe P., Mau-Them F.T., Vitobello A., Goel H.,
RA   Massingham L., Phornphutkul C., Schwab J., Keren B., Charles P.,
RA   Vreeburg M., De Simone L., Hoganson G., Iascone M., Milani D.,
RA   Evenepoel L., Revencu N., Ward D.I., Burns K., Krantz I., Raible S.E.,
RA   Murrell J.R., Wood K., Cho M.T., van Bokhoven H., Muenke M., Kleefstra T.,
RA   Bodmer R., de Brouwer A.P.M.;
RT   "De Novo Variants in CNOT1, a Central Component of the CCR4-NOT Complex
RT   Involved in Gene Expression and RNA and Protein Stability, Cause
RT   Neurodevelopmental Delay.";
RL   Am. J. Hum. Genet. 107:164-172(2020).
CC   -!- FUNCTION: Scaffolding component of the CCR4-NOT complex which is one of
CC       the major cellular mRNA deadenylases and is linked to various cellular
CC       processes including bulk mRNA degradation, miRNA-mediated repression,
CC       translational repression during translational initiation and general
CC       transcription regulation. Additional complex functions may be a
CC       consequence of its influence on mRNA expression. Its scaffolding
CC       function implies its interaction with the catalytic complex module and
CC       diverse RNA-binding proteins mediating the complex recruitment to
CC       selected mRNA 3'UTRs. Involved in degradation of AU-rich element (ARE)-
CC       containing mRNAs probably via association with ZFP36. Mediates the
CC       recruitment of the CCR4-NOT complex to miRNA targets and to the RISC
CC       complex via association with TNRC6A, TNRC6B or TNRC6C. Acts as a
CC       transcriptional repressor. Represses the ligand-dependent
CC       transcriptional activation by nuclear receptors. Involved in the
CC       maintenance of embryonic stem (ES) cell identity.
CC       {ECO:0000269|PubMed:10637334, ECO:0000269|PubMed:16778766,
CC       ECO:0000269|PubMed:21278420, ECO:0000269|PubMed:21976065,
CC       ECO:0000269|PubMed:21984185, ECO:0000269|PubMed:22367759,
CC       ECO:0000269|PubMed:23644599, ECO:0000269|PubMed:27558897,
CC       ECO:0000269|PubMed:32354837}.
CC   -!- SUBUNIT: Component of the CCR4-NOT complex; distinct complexes seem to
CC       exist that differ in the participation of probably mutually exclusive
CC       catalytic subunits (PubMed:10637334, PubMed:16778766, PubMed:19558367,
CC       PubMed:22977175). In the complex, interacts directly with CNOT6,
CC       CNOT6L, CNOT7 or CNOT8 (PubMed:10637334, PubMed:16778766,
CC       PubMed:22977175). Interacts in a ligand-dependent fashion with ESR1 and
CC       RXRA (PubMed:16778766). Interacts with NANOS2, TOB1 and ZFP36
CC       (PubMed:18377426, PubMed:21278420, PubMed:23644599). Interacts with
CC       TNRC6A, TNRC6B or TNRC6C; the interactions are direct (PubMed:21981923,
CC       PubMed:21984185). Interacts with YTHDF2; the interaction is direct and
CC       promotes recruitment of the CCR4-NOT complex to N6-methyladenosine
CC       (m6A)-containing mRNAs, leading to their deadenylation and subsequent
CC       degradation (PubMed:27558897). Interacts with EIF4ENIF1/4E-T
CC       (PubMed:26027925, PubMed:27342281, PubMed:32354837, PubMed:26489469).
CC       {ECO:0000269|PubMed:10637334, ECO:0000269|PubMed:16778766,
CC       ECO:0000269|PubMed:18377426, ECO:0000269|PubMed:19558367,
CC       ECO:0000269|PubMed:21278420, ECO:0000269|PubMed:21981923,
CC       ECO:0000269|PubMed:21984185, ECO:0000269|PubMed:22977175,
CC       ECO:0000269|PubMed:23644599, ECO:0000269|PubMed:26027925,
CC       ECO:0000269|PubMed:26489469, ECO:0000269|PubMed:27342281,
CC       ECO:0000269|PubMed:27558897, ECO:0000269|PubMed:32354837}.
CC   -!- INTERACTION:
CC       A5YKK6; Q3ZCQ2: ANXA2R; NbExp=3; IntAct=EBI-1222758, EBI-21258284;
CC       A5YKK6; Q9UKZ1: CNOT11; NbExp=4; IntAct=EBI-1222758, EBI-2562014;
CC       A5YKK6; Q9NZN8: CNOT2; NbExp=5; IntAct=EBI-1222758, EBI-743033;
CC       A5YKK6; O75175: CNOT3; NbExp=2; IntAct=EBI-1222758, EBI-743073;
CC       A5YKK6; Q9ULM6: CNOT6; NbExp=3; IntAct=EBI-1222758, EBI-2104530;
CC       A5YKK6; Q96LI5: CNOT6L; NbExp=4; IntAct=EBI-1222758, EBI-1046635;
CC       A5YKK6; Q9UIV1: CNOT7; NbExp=7; IntAct=EBI-1222758, EBI-2105113;
CC       A5YKK6; Q9UFF9: CNOT8; NbExp=6; IntAct=EBI-1222758, EBI-742299;
CC       A5YKK6; Q86TB9: PATL1; NbExp=3; IntAct=EBI-1222758, EBI-2562092;
CC       A5YKK6; Q8NDV7: TNRC6A; NbExp=2; IntAct=EBI-1222758, EBI-2269715;
CC       A5YKK6; Q9UPQ9: TNRC6B; NbExp=4; IntAct=EBI-1222758, EBI-947158;
CC       A5YKK6; Q9HCJ0: TNRC6C; NbExp=16; IntAct=EBI-1222758, EBI-6507625;
CC       A5YKK6; P50616: TOB1; NbExp=4; IntAct=EBI-1222758, EBI-723281;
CC       A5YKK6; P22893: Zfp36; Xeno; NbExp=5; IntAct=EBI-1222758, EBI-647803;
CC       A5YKK6-2; P26651: ZFP36; NbExp=4; IntAct=EBI-16057352, EBI-374248;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, P-body {ECO:0000269|PubMed:21976065}.
CC       Nucleus {ECO:0000305|PubMed:21976065}. Note=NANOS2 promotes its
CC       localization to P-body. {ECO:0000250|UniProtKB:Q6ZQ08}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=A5YKK6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=A5YKK6-2; Sequence=VSP_030559;
CC       Name=3;
CC         IsoId=A5YKK6-3; Sequence=VSP_030559, VSP_030562, VSP_030563;
CC       Name=4;
CC         IsoId=A5YKK6-4; Sequence=VSP_030560, VSP_030561;
CC   -!- TISSUE SPECIFICITY: Strongly expressed in brain, heart, thymus, spleen,
CC       kidney, liver, placenta and lung. Weakly expressed in skeletal muscle
CC       and colon. {ECO:0000269|PubMed:10637334}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in embryonic stem (ES) cells.
CC       {ECO:0000269|PubMed:22367759}.
CC   -!- DOMAIN: Contains Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs, a motif known to
CC       be important for the association with nuclear receptors.
CC       {ECO:0000269|PubMed:16778766}.
CC   -!- DISEASE: Holoprosencephaly 12 with or without pancreatic agenesis
CC       (HPE12) [MIM:618500]: An autosomal dominant form of holoprosencephaly,
CC       a structural anomaly of the brain in which the developing forebrain
CC       fails to correctly separate into right and left hemispheres.
CC       Holoprosencephaly is genetically heterogeneous and associated with
CC       several distinct facies and phenotypic variability. HPE12 clinical
CC       features include abnormal forebrain development, dysmorphic features,
CC       global developmental delay, learning difficulties, and congenital
CC       absence of the pancreas in most patients, resulting in early-onset
CC       insulin-dependent diabetes mellitus. Other features may include hearing
CC       loss and absence of the gallbladder. {ECO:0000269|PubMed:31006510,
CC       ECO:0000269|PubMed:31006513}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- DISEASE: Vissers-Bodmer syndrome (VIBOS) [MIM:619033]: An autosomal
CC       dominant disorder characterized by global developmental delay,
CC       intellectual disability of varying degree, speech delay, motor delay,
CC       and hypotonia. Abnormal growth, and cerebral, skeletal, muscle and soft
CC       tissue abnormalities are frequently observed. Many patients have
CC       behavioral problems, including anxiety, obsessive compulsive disorder,
CC       autism spectrum disorder and attention-deficit hyperactivity disorder.
CC       {ECO:0000269|PubMed:32553196}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the CNOT1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF14861.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAH18093.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL117492; CAB55960.1; -; mRNA.
DR   EMBL; BX537840; CAD97851.1; -; mRNA.
DR   EMBL; CR749237; CAH18093.1; ALT_INIT; mRNA.
DR   EMBL; EF553522; ABQ66268.1; -; mRNA.
DR   EMBL; AC009118; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC010287; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC000779; AAH00779.2; -; mRNA.
DR   EMBL; BC024317; AAH24317.1; -; mRNA.
DR   EMBL; BC040523; AAH40523.1; -; mRNA.
DR   EMBL; AB023224; BAA76851.2; -; mRNA.
DR   EMBL; AF110778; AAF14861.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS10799.1; -. [A5YKK6-1]
DR   CCDS; CCDS45501.1; -. [A5YKK6-4]
DR   CCDS; CCDS58468.1; -. [A5YKK6-2]
DR   PIR; T17270; T17270.
DR   RefSeq; NP_001252541.1; NM_001265612.1. [A5YKK6-2]
DR   RefSeq; NP_057368.3; NM_016284.4. [A5YKK6-1]
DR   RefSeq; NP_996882.1; NM_206999.2. [A5YKK6-4]
DR   PDB; 4C0D; X-ray; 3.20 A; A=1565-2371.
DR   PDB; 4CQO; X-ray; 2.80 A; A/C=1833-2361.
DR   PDB; 4CRU; X-ray; 1.65 A; A=1356-1607.
DR   PDB; 4CRV; X-ray; 2.05 A; A=1356-1607.
DR   PDB; 4CRW; X-ray; 1.75 A; A=1093-1317.
DR   PDB; 4CT4; X-ray; 2.30 A; A/C=1063-1314.
DR   PDB; 4CT6; X-ray; 2.10 A; A=1352-1594.
DR   PDB; 4CT7; X-ray; 1.90 A; A=1352-1594.
DR   PDB; 4GMJ; X-ray; 2.70 A; A/C/E=1093-1317.
DR   PDB; 4GML; X-ray; 2.90 A; A/B/C/D/E/F=1093-1317.
DR   PDB; 4J8S; X-ray; 1.55 A; A=800-1004.
DR   PDB; 5ANR; X-ray; 2.10 A; A=1063-1314.
DR   PDB; 5FU6; X-ray; 2.90 A; A/D=1833-2361.
DR   PDB; 5FU7; X-ray; 3.10 A; A/E=1833-2361.
DR   PDB; 5ONA; X-ray; 2.70 A; A/D=1351-1588.
DR   PDB; 7VOI; X-ray; 4.38 A; A=1093-1317.
DR   PDB; 8BFI; X-ray; 3.00 A; A=1-687.
DR   PDBsum; 4C0D; -.
DR   PDBsum; 4CQO; -.
DR   PDBsum; 4CRU; -.
DR   PDBsum; 4CRV; -.
DR   PDBsum; 4CRW; -.
DR   PDBsum; 4CT4; -.
DR   PDBsum; 4CT6; -.
DR   PDBsum; 4CT7; -.
DR   PDBsum; 4GMJ; -.
DR   PDBsum; 4GML; -.
DR   PDBsum; 4J8S; -.
DR   PDBsum; 5ANR; -.
DR   PDBsum; 5FU6; -.
DR   PDBsum; 5FU7; -.
DR   PDBsum; 5ONA; -.
DR   PDBsum; 7VOI; -.
DR   PDBsum; 8BFI; -.
DR   AlphaFoldDB; A5YKK6; -.
DR   SMR; A5YKK6; -.
DR   BioGRID; 116660; 287.
DR   ComplexPortal; CPX-2522; CCR4-NOT mRNA deadenylase complex, CNOT6L-CNOT7 variant.
DR   ComplexPortal; CPX-2535; CCR4-NOT mRNA deadenylase complex, CNOT6L-CNOT8 variant.
DR   ComplexPortal; CPX-2849; CCR4-NOT mRNA deadenylase complex, CNOT6-CNOT8 variant.
DR   ComplexPortal; CPX-707; CCR4-NOT mRNA deadenylase complex, CNOT6-CNOT7 variant.
DR   CORUM; A5YKK6; -.
DR   DIP; DIP-44954N; -.
DR   ELM; A5YKK6; -.
DR   IntAct; A5YKK6; 119.
DR   MINT; A5YKK6; -.
DR   STRING; 9606.ENSP00000320949; -.
DR   ChEMBL; CHEMBL4105919; -.
DR   CarbonylDB; A5YKK6; -.
DR   GlyCosmos; A5YKK6; 15 sites, 2 glycans.
DR   GlyGen; A5YKK6; 21 sites, 2 O-linked glycans (21 sites).
DR   iPTMnet; A5YKK6; -.
DR   MetOSite; A5YKK6; -.
DR   PhosphoSitePlus; A5YKK6; -.
DR   SwissPalm; A5YKK6; -.
DR   BioMuta; CNOT1; -.
DR   EPD; A5YKK6; -.
DR   jPOST; A5YKK6; -.
DR   MassIVE; A5YKK6; -.
DR   MaxQB; A5YKK6; -.
DR   PaxDb; A5YKK6; -.
DR   PeptideAtlas; A5YKK6; -.
DR   ProteomicsDB; 759; -. [A5YKK6-1]
DR   ProteomicsDB; 760; -. [A5YKK6-2]
DR   ProteomicsDB; 761; -. [A5YKK6-3]
DR   ProteomicsDB; 762; -. [A5YKK6-4]
DR   Antibodypedia; 29121; 104 antibodies from 21 providers.
DR   DNASU; 23019; -.
DR   Ensembl; ENST00000317147.10; ENSP00000320949.5; ENSG00000125107.19. [A5YKK6-1]
DR   Ensembl; ENST00000441024.6; ENSP00000413113.2; ENSG00000125107.19. [A5YKK6-4]
DR   Ensembl; ENST00000567188.5; ENSP00000456649.1; ENSG00000125107.19. [A5YKK6-3]
DR   Ensembl; ENST00000569240.5; ENSP00000455635.1; ENSG00000125107.19. [A5YKK6-2]
DR   GeneID; 23019; -.
DR   KEGG; hsa:23019; -.
DR   MANE-Select; ENST00000317147.10; ENSP00000320949.5; NM_016284.5; NP_057368.3.
DR   UCSC; uc002enu.6; human. [A5YKK6-1]
DR   AGR; HGNC:7877; -.
DR   CTD; 23019; -.
DR   DisGeNET; 23019; -.
DR   GeneCards; CNOT1; -.
DR   HGNC; HGNC:7877; CNOT1.
DR   HPA; ENSG00000125107; Low tissue specificity.
DR   MalaCards; CNOT1; -.
DR   MIM; 604917; gene.
DR   MIM; 618500; phenotype.
DR   MIM; 619033; phenotype.
DR   neXtProt; NX_A5YKK6; -.
DR   OpenTargets; ENSG00000125107; -.
DR   Orphanet; 556955; Pancreatic agenesis-holoprosencephaly syndrome.
DR   PharmGKB; PA26672; -.
DR   VEuPathDB; HostDB:ENSG00000125107; -.
DR   eggNOG; KOG1831; Eukaryota.
DR   GeneTree; ENSGT00390000014869; -.
DR   HOGENOM; CLU_000286_3_0_1; -.
DR   InParanoid; A5YKK6; -.
DR   OMA; IDEYHCY; -.
DR   OrthoDB; 1329322at2759; -.
DR   PhylomeDB; A5YKK6; -.
DR   TreeFam; TF105630; -.
DR   PathwayCommons; A5YKK6; -.
DR   Reactome; R-HSA-429947; Deadenylation of mRNA.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   SignaLink; A5YKK6; -.
DR   SIGNOR; A5YKK6; -.
DR   BioGRID-ORCS; 23019; 542 hits in 1182 CRISPR screens.
DR   ChiTaRS; CNOT1; human.
DR   GeneWiki; CNOT1; -.
DR   GenomeRNAi; 23019; -.
DR   Pharos; A5YKK6; Tbio.
DR   PRO; PR:A5YKK6; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; A5YKK6; protein.
DR   Bgee; ENSG00000125107; Expressed in left testis and 202 other tissues.
DR   ExpressionAtlas; A5YKK6; baseline and differential.
DR   Genevisible; A5YKK6; HS.
DR   GO; GO:0030014; C:CCR4-NOT complex; IDA:UniProtKB.
DR   GO; GO:0030015; C:CCR4-NOT core complex; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0000932; C:P-body; IDA:UniProtKB.
DR   GO; GO:0005778; C:peroxisomal membrane; HDA:UniProtKB.
DR   GO; GO:0070016; F:armadillo repeat domain binding; IPI:BHF-UCL.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:BHF-UCL.
DR   GO; GO:0030331; F:nuclear estrogen receptor binding; IDA:UniProtKB.
DR   GO; GO:0042974; F:nuclear retinoic acid receptor binding; IDA:UniProtKB.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0035195; P:miRNA-mediated gene silencing; IDA:BHF-UCL.
DR   GO; GO:0033147; P:negative regulation of intracellular estrogen receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:BHF-UCL.
DR   GO; GO:0000288; P:nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay; IBA:GO_Central.
DR   GO; GO:0000289; P:nuclear-transcribed mRNA poly(A) tail shortening; NAS:ComplexPortal.
DR   GO; GO:0010606; P:positive regulation of cytoplasmic mRNA processing body assembly; IDA:UniProtKB.
DR   GO; GO:0061014; P:positive regulation of mRNA catabolic process; IMP:BHF-UCL.
DR   GO; GO:1900153; P:positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay; IMP:UniProtKB.
DR   GO; GO:0060213; P:positive regulation of nuclear-transcribed mRNA poly(A) tail shortening; IDA:BHF-UCL.
DR   GO; GO:2000036; P:regulation of stem cell population maintenance; IMP:UniProtKB.
DR   GO; GO:0090503; P:RNA phosphodiester bond hydrolysis, exonucleolytic; IEA:GOC.
DR   GO; GO:0001829; P:trophectodermal cell differentiation; IEA:Ensembl.
DR   CDD; cd20710; NOT1_connector; 1.
DR   DisProt; DP02524; -.
DR   Gene3D; 1.25.40.180; -; 1.
DR   Gene3D; 1.25.40.790; -; 1.
DR   Gene3D; 1.25.40.800; -; 1.
DR   Gene3D; 1.25.40.840; CCR4-NOT transcription complex subunit 1 TTP binding domain; 1.
DR   IDEAL; IID00423; -.
DR   InterPro; IPR007196; CCR4-Not_Not1_C.
DR   InterPro; IPR032191; CNOT1_CAF1_bind.
DR   InterPro; IPR024557; CNOT1_dom_4.
DR   InterPro; IPR032194; CNOT1_HEAT.
DR   InterPro; IPR032193; CNOT1_TTP_bind.
DR   InterPro; IPR038535; CNOT1_TTP_bind_sf.
DR   InterPro; IPR040398; Not1.
DR   PANTHER; PTHR13162; CCR4-NOT TRANSCRIPTION COMPLEX; 1.
DR   PANTHER; PTHR13162:SF8; CCR4-NOT TRANSCRIPTION COMPLEX SUBUNIT 1; 1.
DR   Pfam; PF16415; CNOT1_CAF1_bind; 1.
DR   Pfam; PF16418; CNOT1_HEAT; 1.
DR   Pfam; PF16417; CNOT1_TTP_bind; 1.
DR   Pfam; PF12842; DUF3819; 1.
DR   Pfam; PF04054; Not1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autism spectrum disorder; Cytoplasm;
KW   Developmental protein; Disease variant; Holoprosencephaly;
KW   Intellectual disability; Nucleus; Phosphoprotein; Reference proteome;
KW   Repressor; RNA-mediated gene silencing; Transcription;
KW   Transcription regulation; Translation regulation.
FT   CHAIN           1..2376
FT                   /note="CCR4-NOT transcription complex subunit 1"
FT                   /id="PRO_0000315541"
FT   REGION          720..768
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          800..1015
FT                   /note="Interaction with ZFP36"
FT   REGION          1090..1605
FT                   /note="Interaction with CNOT6, CNOT6L, CNOT7 and CNOT8"
FT                   /evidence="ECO:0000269|PubMed:22977175"
FT   REGION          1315..1352
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           153..157
FT                   /note="LXXLL"
FT   MOTIF           181..185
FT                   /note="LXXLL"
FT   MOTIF           223..227
FT                   /note="LXXLL"
FT   MOTIF           570..574
FT                   /note="LXXLL"
FT   MOTIF           1639..1643
FT                   /note="LXXLL"
FT   MOTIF           1942..1946
FT                   /note="LXXLL"
FT   MOTIF           2096..2100
FT                   /note="LXXLL"
FT   COMPBIAS        723..768
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1329..1352
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         318
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1061
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         822..827
FT                   /note="SKMKPS -> T (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10231032,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_030559"
FT   VAR_SEQ         1479..1551
FT                   /note="TASPQQREMMDQAAAQLAQDNCELACCFIQKTAVEKAGPEMDKRLATEFELR
FT                   KHARQEGRRYCDPVVLTYQAE -> VSWLFPWYRYKTYYCLSVIIFFFVYIWHWALPLI
FT                   LNNHHICLMSSIILDCNSVRQSIMSVCFFFFLLYSQHDV (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_030560"
FT   VAR_SEQ         1552..2376
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_030561"
FT   VAR_SEQ         2152..2155
FT                   /note="VDML -> SLTL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_030562"
FT   VAR_SEQ         2156..2376
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_030563"
FT   VARIANT         26..2376
FT                   /note="Missing (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084311"
FT   VARIANT         33..2376
FT                   /note="Missing (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084312"
FT   VARIANT         396..2376
FT                   /note="Missing (in VIBOS; dbSNP:rs1567420855)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084313"
FT   VARIANT         535
FT                   /note="R -> C (in HPE12; dbSNP:rs1567417422)"
FT                   /evidence="ECO:0000269|PubMed:31006513"
FT                   /id="VAR_083066"
FT   VARIANT         603
FT                   /note="D -> A (in dbSNP:rs17854028)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_038254"
FT   VARIANT         642
FT                   /note="Q -> E (in VIBOS; uncertain pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084314"
FT   VARIANT         897
FT                   /note="E -> K (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084315"
FT   VARIANT         900
FT                   /note="R -> C (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084316"
FT   VARIANT         1038
FT                   /note="T -> I (in VIBOS; uncertain pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084317"
FT   VARIANT         1089
FT                   /note="V -> L (in VIBOS; uncertain pathological
FT                   significance; dbSNP:rs2040438229)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084318"
FT   VARIANT         1148
FT                   /note="L -> P (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084319"
FT   VARIANT         1188
FT                   /note="D -> G (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084320"
FT   VARIANT         1241
FT                   /note="K -> R (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084321"
FT   VARIANT         1419
FT                   /note="T -> A (in VIBOS; dbSNP:rs1038725612)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084322"
FT   VARIANT         1428
FT                   /note="F -> S (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084323"
FT   VARIANT         1478
FT                   /note="R -> C (in VIBOS; dbSNP:rs1567396193)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084324"
FT   VARIANT         1494
FT                   /note="Q -> H (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084325"
FT   VARIANT         1572
FT                   /note="Y -> D (in VIBOS)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084326"
FT   VARIANT         2216
FT                   /note="N -> S (in VIBOS; dbSNP:rs1184460054)"
FT                   /evidence="ECO:0000269|PubMed:32553196"
FT                   /id="VAR_084327"
FT   MUTAGEN         1208
FT                   /note="K->E: Impairs interaction with CNOT7; when
FT                   associated with Y-1212 and E-1218."
FT                   /evidence="ECO:0000269|PubMed:22977175"
FT   MUTAGEN         1209
FT                   /note="P->Y: Abolishes interaction with CNOT7; when
FT                   associated with Y-1257."
FT   MUTAGEN         1212
FT                   /note="H->Y: Impairs interaction with CNOT7; when
FT                   associated with E-1208 and E-1218."
FT                   /evidence="ECO:0000269|PubMed:22977175"
FT   MUTAGEN         1218
FT                   /note="K->E: Impairs interaction with CNOT7; when
FT                   associated with E-1208 and Y-1212."
FT                   /evidence="ECO:0000269|PubMed:22977175"
FT   MUTAGEN         1251
FT                   /note="V->R: Abolishes interaction with CNOT7."
FT   MUTAGEN         1257
FT                   /note="P->Y: Abolishes interaction with CNOT7; when
FT                   associated with Y-1209."
FT   CONFLICT        18
FT                   /note="D -> G (in Ref. 1; CAD97851)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        323
FT                   /note="D -> G (in Ref. 1; CAD97851)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        922
FT                   /note="E -> G (in Ref. 1; ABQ66268)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1063
FT                   /note="K -> R (in Ref. 1; CAH18093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1417
FT                   /note="M -> V (in Ref. 1; CAD97851)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1799
FT                   /note="R -> G (in Ref. 1; CAD97851)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1936
FT                   /note="L -> P (in Ref. 1; CAH18093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2198..2200
FT                   /note="SNL -> RTV (in Ref. 6; AAF14861)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2358
FT                   /note="Q -> R (in Ref. 1; ABQ66268)"
FT                   /evidence="ECO:0000305"
FT   TURN            830..832
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   TURN            838..840
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           841..856
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           866..877
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           882..897
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           899..904
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           907..922
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           929..942
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           949..961
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           962..967
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           969..976
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           981..983
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           986..996
FT                   /evidence="ECO:0007829|PDB:4J8S"
FT   HELIX           1076..1082
FT                   /evidence="ECO:0007829|PDB:5ANR"
FT   HELIX           1093..1104
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   TURN            1108..1110
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1111..1121
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1124..1126
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1127..1137
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   TURN            1138..1141
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1143..1145
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1146..1156
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1159..1177
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1181..1183
FT                   /evidence="ECO:0007829|PDB:5ANR"
FT   HELIX           1186..1202
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1204..1206
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   TURN            1212..1214
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1217..1227
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1229..1243
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1244..1248
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   TURN            1250..1252
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1257..1271
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1277..1289
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1294..1296
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1302..1304
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1306..1310
FT                   /evidence="ECO:0007829|PDB:4CRW"
FT   HELIX           1359..1361
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1367..1369
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1371..1373
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1381..1385
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1387..1392
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1393..1427
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   TURN            1428..1430
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1434..1476
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1482..1522
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1524..1535
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1543..1552
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1555..1557
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   STRAND          1561..1563
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1566..1569
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1570..1577
FT                   /evidence="ECO:0007829|PDB:4CRU"
FT   HELIX           1848..1865
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           1866..1868
FT                   /evidence="ECO:0007829|PDB:5FU6"
FT   HELIX           1870..1885
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   STRAND          1888..1891
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           1892..1915
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           1926..1948
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   STRAND          1950..1954
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           1957..1981
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           1982..1984
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           1988..2000
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2006..2009
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2012..2025
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   TURN            2028..2030
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2032..2034
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2035..2042
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2045..2052
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2056..2058
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2061..2080
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2086..2105
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2107..2112
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2114..2120
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2126..2133
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   STRAND          2145..2147
FT                   /evidence="ECO:0007829|PDB:4C0D"
FT   HELIX           2152..2154
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2157..2159
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2168..2171
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2174..2186
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2191..2200
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   STRAND          2204..2207
FT                   /evidence="ECO:0007829|PDB:5FU6"
FT   STRAND          2208..2210
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2212..2232
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   TURN            2239..2241
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   STRAND          2242..2245
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2246..2257
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2260..2271
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   STRAND          2276..2278
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2279..2293
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   STRAND          2296..2298
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2299..2312
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   STRAND          2313..2316
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2320..2331
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2337..2339
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   TURN            2342..2344
FT                   /evidence="ECO:0007829|PDB:4CQO"
FT   HELIX           2348..2360
FT                   /evidence="ECO:0007829|PDB:4CQO"
SQ   SEQUENCE   2376 AA;  266939 MW;  937A0899537BA615 CRC64;
     MNLDSLSLAL SQISYLVDNL TKKNYRASQQ EIQHIVNRHG PEADRHLLRC LFSHVDFSGD
     GKSSGKDFHQ TQFLIQECAL LITKPNFIST LSYAIDNPLH YQKSLKPAPH LFAQLSKVLK
     LSKVQEVIFG LALLNSSSSD LRGFAAQFIK QKLPDLLRSY IDADVSGNQE GGFQDIAIEV
     LHLLLSHLLF GQKGAFGVGQ EQIDAFLKTL RRDFPQERCP VVLAPLLYPE KRDILMDRIL
     PDSGGVAKTM MESSLADFMQ EVGYGFCASI EECRNIIVQF GVREVTAAQV ARVLGMMART
     HSGLTDGIPL QSISAPGSGI WSDGKDKSDG AQAHTWNVEV LIDVLKELNP SLNFKEVTYE
     LDHPGFQIRD SKGLHNVVYG IQRGLGMEVF PVDLIYRPWK HAEGQLSFIQ HSLINPEIFC
     FADYPCHTVA TDILKAPPED DNREIATWKS LDLIESLLRL AEVGQYEQVK QLFSFPIKHC
     PDMLVLALLQ INTSWHTLRH ELISTLMPIF LGNHPNSAII LHYAWHGQGQ SPSIRQLIMH
     AMAEWYMRGE QYDQAKLSRI LDVAQDLKAL SMLLNGTPFA FVIDLAALAS RREYLKLDKW
     LTDKIREHGE PFIQACMTFL KRRCPSILGG LAPEKDQPKS AQLPPETLAT MLACLQACAG
     SVSQELSETI LTMVANCSNV MNKARQPPPG VMPKGRPPSA SSLDAISPVQ IDPLAGMTSL
     SIGGSAAPHT QSMQGFPPNL GSAFSTPQSP AKAFPPLSTP NQTTAFSGIG GLSSQLPVGG
     LGTGSLTGIG TGALGLPAVN NDPFVQRKLG TSGLNQPTFQ QSKMKPSDLS QVWPEANQHF
     SKEIDDEANS YFQRIYNHPP HPTMSVDEVL EMLQRFKDST IKREREVFNC MLRNLFEEYR
     FFPQYPDKEL HITACLFGGI IEKGLVTYMA LGLALRYVLE ALRKPFGSKM YYFGIAALDR
     FKNRLKDYPQ YCQHLASISH FMQFPHHLQE YIEYGQQSRD PPVKMQGSIT TPGSIALAQA
     QAQAQVPAKA PLAGQVSTMV TTSTTTTVAK TVTVTRPTGV SFKKDVPPSI NTTNIDTLLV
     ATDQTERIVE PPENIQEKIA FIFNNLSQSN MTQKVEELKE TVKEEFMPWV SQYLVMKRVS
     IEPNFHSLYS NFLDTLKNPE FNKMVLNETY RNIKVLLTSD KAAANFSDRS LLKNLGHWLG
     MITLAKNKPI LHTDLDVKSL LLEAYVKGQQ ELLYVVPFVA KVLESSIRSV VFRPPNPWTM
     AIMNVLAELH QEHDLKLNLK FEIEVLCKNL ALDINELKPG NLLKDKDRLK NLDEQLSAPK
     KDVKQPEELP PITTTTTSTT PATNTTCTAT VPPQPQYSYH DINVYSLAGL APHITLNPTI
     PLFQAHPQLK QCVRQAIERA VQELVHPVVD RSIKIAMTTC EQIVRKDFAL DSEESRMRIA
     AHHMMRNLTA GMAMITCREP LLMSISTNLK NSFASALRTA SPQQREMMDQ AAAQLAQDNC
     ELACCFIQKT AVEKAGPEMD KRLATEFELR KHARQEGRRY CDPVVLTYQA ERMPEQIRLK
     VGGVDPKQLA VYEEFARNVP GFLPTNDLSQ PTGFLAQPMK QAWATDDVAQ IYDKCITELE
     QHLHAIPPTL AMNPQAQALR SLLEVVVLSR NSRDAIAALG LLQKAVEGLL DATSGADADL
     LLRYRECHLL VLKALQDGRA YGSPWCNKQI TRCLIECRDE YKYNVEAVEL LIRNHLVNMQ
     QYDLHLAQSM ENGLNYMAVA FAMQLVKILL VDERSVAHVT EADLFHTIET LMRINAHSRG
     NAPEGLPQLM EVVRSNYEAM IDRAHGGPNF MMHSGISQAS EYDDPPGLRE KAEYLLREWV
     NLYHSAAAGR DSTKAFSAFV GQMHQQGILK TDDLITRFFR LCTEMCVEIS YRAQAEQQHN
     PAANPTMIRA KCYHNLDAFV RLIALLVKHS GEATNTVTKI NLLNKVLGIV VGVLLQDHDV
     RQSEFQQLPY HRIFIMLLLE LNAPEHVLET INFQTLTAFC NTFHILRPTK APGFVYAWLE
     LISHRIFIAR MLAHTPQQKG WPMYAQLLID LFKYLAPFLR NVELTKPMQI LYKGTLRVLL
     VLLHDFPEFL CDYHYGFCDV IPPNCIQLRN LILSAFPRNM RLPDPFTPNL KVDMLSEINI
     APRILTNFTG VMPPQFKKDL DSYLKTRSPV TFLSDLRSNL QVSNEPGNRY NLQLINALVL
     YVGTQAIAHI HNKGSTPSMS TITHSAHMDI FQNLAVDLDT EGRYLFLNAI ANQLRYPNSH
     THYFSCTMLY LFAEANTEAI QEQITRVLLE RLIVNRPHPW GLLITFIELI KNPAFKFWNH
     EFVHCAPEIE KLFQSVAQCC MGQKQAQQVM EGTGAS
//
